Clinical Trials Logo

Dermatitis clinical trials

View clinical trials related to Dermatitis.

Filter by:

NCT ID: NCT00891709 Completed - Atopic Dermatitis Clinical Trials

LEO 29102 Single and Multiple Dose Study by Dermal Application

Start date: March 2009
Phase: Phase 1
Study type: Interventional

The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy male subjects. The study is divided into one single dose part followed by a multiple dose part.

NCT ID: NCT00890968 Completed - Hand Dermatoses Clinical Trials

Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis

TAC-202
Start date: April 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Triamcinolone Acetonide (TAC) DuraPeel is safe and effective in the treatment of hand dermatitis.

NCT ID: NCT00886587 Completed - Atopic Dermatitis Clinical Trials

To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children

Start date: April 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety of the investigational study product and see how well it works to relieve signs and symptoms of children with mild to moderate Atopic Dermatitis (AD), also known as eczema, in comparison to that of a similar marketed product. This study is being done to see how safe the investigational new study product is and how well it will work to treat AD in children, by making AD visually better, and reducing the amount of itch.

NCT ID: NCT00884325 Completed - Atopic Dermatitis Clinical Trials

Management of Pruritus With Xyzal in Atopic Dermatitis

Start date: February 2009
Phase: Phase 4
Study type: Interventional

It is historically well known that the management of pruritus in atopic dermatitis is very difficult. Most of the patients are not controlled with traditional antihistamines such as Clarinex, Claritin, and Allegra. It will be a welcome addition to our treatment armamentarium if a drug such as Xyzal can control pruritus associated with atopic dermatitis.

NCT ID: NCT00883311 Completed - Atopic Dermatitis Clinical Trials

A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis

Start date: January 2009
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether the topical application of BRT-FC-83C is effective in the treatment of mild to moderate atopic dermatitis.

NCT ID: NCT00882245 Completed - Atopic Dermatitis Clinical Trials

Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis

Start date: April 2009
Phase: Phase 2
Study type: Interventional

Atopic Dermatitis is a chronic inflammatory skin disease that affect 10 to 15% of children and 2 to 10% of adults. AD is characterised by an itchy skin eruption and may cover large parts of the body. The exact cause is unknown but is thought to be an interplay between genetic and and environmental factors. The objective of this study is to determine whether SRD441 ointment is a safe and effective therapy for mild to moderate Atopic Dermatitis.

NCT ID: NCT00879944 Completed - Psoriasis Clinical Trials

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

Start date: May 2009
Phase: N/A
Study type: Observational

The object of this research study is to examine these associations in children as very little is known about psoriasis and cardiovascular risk factors in the pediatric population.

NCT ID: NCT00879424 Completed - Atopic Dermatitis Clinical Trials

Vitamin D Supplementation in Childhood Atopic Dermatitis

Start date: February 2009
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate the therapeutic role of vitamin D supplementation in a subset of patients with atopic dermatitis (AD): children with disease onset or worsening in the winter. The investigators hypothesis is that (1) vitamin D supplementation in patients with either wintertime onset or exacerbation of AD will improve Eczema Area and Severity Index (EASI) scores, and (2) vitamin D supplementation will improve the Investigator's Global Assessment.

NCT ID: NCT00878670 Completed - Atopic Dermatitis Clinical Trials

Investigation of Efficacy and Safety of EPOGAM

Start date: March 2009
Phase: Phase 4
Study type: Interventional

In this study it will be investigated if patients with atopic dermatitis responding to EPOGAM treatment, show a significant increase of dihomo-gamma-linolic acid in the blood.

NCT ID: NCT00876642 Completed - Clinical trials for Radiation Dermatitis

Trial Comparing Best Supportive Care to Aloe Vera Gel

Start date: March 2007
Phase: Phase 3
Study type: Interventional

Radiation therapy (RT) has been a component of breast cancer treatment for almost 100 years. Although initially used for the treatment of chest wall recurrences after mastectomy and for advanced inoperable disease, RT has evolved into a critical component of early therapy for women with an intact breast following lumpectomy and for mastectomized women who are at high risk for local failure. Currently breast cancer patients need a multidisciplinary management including surgery, chemotherapy and radiotherapy, radiotherapy has a significant role in loco regional control of the disease. It is estimated that 87% of these women will develop some degree of radiation-induced dermatitis, varying from mild to brisk erythema or even moist desquamation. Topical agents, such as corticosteroid creams and other products including Aquaphor (Beirsdorf Inc, Wilton, CT), and trolamine (Biafine; Genmedix Ltd, France), are commonly prescribed at the onset of radiation dermatitis or, in some institutions, at the beginning of radiotherapy. The aim of this randomized phase III study was to assess the effectiveness of aloe vera cream for the prevention of acute radiation-induced dermatitis of grade 2 or higher during postoperative radiotherapy for breast cancer, compared to best supportive care. The secondary objectives were to assess pain, treatment interruption as a result of skin reactions, and the quantity of life during the treatment.